Trails Edge Capital Partners, LP → Contineum Therapeutics, Inc. CTNM

Stake: — Shares: — CUSIP: 21217B100 Class: Class A Common Stock, $0.001 par value per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 24/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
2 NPORT-P mutual funds holding CUSIP
Moderate short days-to-cover (3.6 DTC)
Short interest building (+25.5% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-09-30

DTC 3.62

3,067,588 shares short · +25.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $8.68M

Point72 Asset Mgmt

Other Filings by Trails Edge Capital Partners, LP

Filed	Form	Issuer	Stake	Shares
2026-07-21	SCHEDULE 13G	Research Alliance Corporation IV	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →